Company overview
InterVenn Biosciences offers GlycoVision™, an AI-powered glycoproteomics platform using LC-MS/MS for high-throughput biomarker discovery from serum or plasma samples. The platform enables site-specific protein glycosylation analysis for precision medicine applications in oncology, diagnostics, and drug development. Key products include the GlycoKnow™ Ovarian cancer liquid biopsy test, with partnerships expanding clinical workflows and global lab facilities.
InterVenn Biosciences is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include glycoproteomics, biomarker discovery, glycovision, liquid biopsy, ovarian cancer diagnostics.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://intervenn.com
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- glycoproteomics, biomarker discovery, glycovision, liquid biopsy, ovarian cancer diagnostics
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What is InterVenn's core technology platform?
- GlycoVision™ integrates LC-MS/MS with AI/ML for high-resolution glycoproteome analysis, identifying glycopeptide biomarkers with >99% concordance to expert analysis.
- What specific diagnostic products does InterVenn offer?
- GlycoKnow™ Ovarian is a blood-based liquid biopsy test that distinguishes ovarian cancer from benign pelvic masses, offered as a laboratory-developed test.
- What are InterVenn's geographic capabilities?
- InterVenn operates facilities in the US (California, South San Francisco), Asia-Pacific (Kuala Lumpur, Philippines), and Australia for clinical research, software development, and technical support.
Related editorial coverage
- Tissue TMB Superior to Blood TMB in Predicting Immunotherapy Response, Cleveland Clinic Study Finds
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
Explore lab tools and QA/QC resources for R&D teams.
